Heart failure is a major cause of cardiovascular morbidity and mortality and its incidence is on the increase. The pathophysiology of heart failure is multi-factorial but recent studies suggest that aldosterone plays an important and independent role in its progression. Emerging evidence now suggests that aldosterone exerts renal-independent effects. It binds to its mineralocorticoid receptor to produce direct effects on the myocardium and vasculature, leading to damaging processes such as hypertrophy, necrosis, fibrosis and endothelial dysfunction, factors known to contribute to the pathophysiology of heart failure. Mineralocorticoid receptor antagonists have thus emerged as a new paradigm for the treatment of heart failure. The benefits of these agents on both morbidity and mortality when used in patients with chronic symptomatic heart failure have been demonstrated by recent trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1742-1241.2006.00996.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Site-Specific Ventricular Tachycardia Inducibility.
JACC Clin Electrophysiol
January 2025
Vanderbilt Heart and Vascular Institute, Nashville, Tennessee, USA. Electronic address:
Background: Programmed electrical stimulation (PES) is an essential part of ventricular tachycardia (VT) ablation procedures, but VT is not always inducible, usually for reasons that are not clear.
Objectives: This study sought to review pacing site-specific failure of PES to induce scar-related VT and to provide a potential mechanistic explanation of the phenomena using a computer simulation.
Methods: Six patients in whom aggressive PES from traditional RV pacing sites failed to induce VT, but VT was easily inducible from a nontraditional site, were reviewed.
Antiobesity Medications in Patients With Heart Failure: A Clinical Protocol and Preliminary Single-Center Experience.
JACC Heart Fail
January 2025
Division of Cardiology, CardioVascular Center, Tufts Medical Center, Boston, Massachusetts, USA; Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA. Electronic address:
24-Month Outcomes of Endovascular Baroreflex Amplification With the MobiusHD Device in Heart Failure With Reduced Ejection Fraction.
JACC Heart Fail
January 2025
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Adeno-Associated Viruses as Gene Delivery Tools for Diabetic Heart Disease and Failure: Key Considerations for Clinicians and Preclinical Researchers.
Heart Lung Circ
January 2025
Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Burwood, Vic, Australia; Department of Paediatrics, University of Melbourne, Parkville, Vic, Australia. Electronic address:
Diabetes is becoming more common worldwide, and people with diabetes are twice as likely to experience heart problems compared to those without diabetes. These cardiovascular complications are the foremost cause of mortality among people with diabetes. A specific form of heart failure known as "diabetic cardiomyopathy" can develop in individuals with diabetes.
View Article and Find Full Text PDFTranscatheter edge-to-edge mitral repair for secondary mitral regurgitation: New evidence, but many questions remain.
Arch Cardiovasc Dis
January 2025
Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON K1Y 4W7, Canada; School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!